A CASE REPORT: ACUTE MYELOID LEUKEMIA

Acute myeloid leukemia (AML) is a complex blood cancer marked by a range of genetic and epigenetic alterations that impact the risk of patients and their responses to treatment. As we acquire more insights from detailed genetic research, it becomes evident that a comprehensive profile of emerging mutations is vital for personalizing therapy and enhancing patient outcomes. The articles under review emphasize how certain mutations, particularly TET2, ETV6, SATB1, EZH2, PTPN11, and U2AF1, influence prognosis, resistance to therapies, and the development of targeted and epigenetic treatments. Focusing on regulators affect clinical behaviour, including DNA hypermethylation and chemotherapy resistance. Additionally, disruptions in ETV6 provide valuable insights into the alterations in blood cell production processes.